Eli Lilly

News

High-dose semaglutide ramps up weight loss, says Novo

Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.

News

Lilly nets a second FDA okay for Omvoh, in Crohn's disease

Eli Lilly picks up a second FDA approval for IL-23 inhibitor Omvoh in Crohn's disease, but will it kickstart sales growth?

News

Lilly trims sales forecast on weaker obesity/diabetes growth

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies.

News

Lilly nets Scorpion cancer drug in $2.5bn licensing deal

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

Patient using a positive airway pressure mask

Lilly grabs first-ever FDA nod for a sleep apnoea drug

Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea, which affects millions in the US.

High-dose semaglutide ramps up weight loss, says Novo

Lilly nets a second FDA okay for Omvoh, in Crohn's disease

Lilly trims sales forecast on weaker obesity/diabetes growth

Lilly nets Scorpion cancer drug in $2.5bn licensing deal

11 blockbuster drugs to look out for in 2025

Lilly grabs first-ever FDA nod for a sleep apnoea drug

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Eli Lilly

Editor's Picks